Merck's Keytruda meets main goal in lung cancer trial Merck & Co said on Monday a late-stage trial testing its blockbuster cancer drug, Keytruda, met the main goal of helping previously untreated lung cancer patients live longer, sending its shares up 3 percent in premarket trade.
